Molecular Partners AG (MOLN) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Summary

Molecular Partners AG (Molecular Partners) is a clinical stage biopharmaceutical company that provides biological drugs. The company provides advanced pipeline products such as abicipar, a designed ankyrin repeat protein based anti-angiogenic drug developed for diabetic macular edema and wet age- macular degeneration. It develops drugs on DARPin base technology and other product candidates. Molecular Partners develops products for ophthalmic conditions, cancer, immune disorders and other indications. The company also provides clinical trial services and small protein therapies called Darpin therapeutics. It has partnership with pharmaceutical company to strengthen drug platforms through in-house development, licensing, collaboration, and others. Molecular Partners is headquartered in Zurich, Switzerland.

Molecular Partners AG (MOLN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

It derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.



List of Tables 4
List of Figures 4
Molecular Partners AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Molecular Partners AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Molecular Partners AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Molecular Partners AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Molecular Partners AG, Medical Devices Deals, 2012 to YTD 2018 9
Molecular Partners AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Molecular Partners AG, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Molecular Partners and AstraZeneca Enter into Partnership 11
Molecular Partners Reinforces Partnership with Allergan 12
Allergan Exercises Option Agreement with Molecular Partners 13
Equity Offering 14
Molecular Partners Raises USD31.7 Million in Private Placement of Shares 14
Molecular Partners Announces Partial Exercise of Underwriters Option for IPO for USD108 Million 15
Molecular Partners AG - Key Competitors 17
Molecular Partners AG - Key Employees 18
Molecular Partners AG - Locations And Subsidiaries 19
Head Office 19
Recent Developments 20
Financial Announcements 20
Feb 08, 2018: Molecular Partners Reports Significant Progress of Pipeline and Preliminary Unaudited Key Financials for 2017 - Key Value Inflection Points in 2018 20
Aug 30, 2017: Molecular Partners reports key financials and corporate highlights for H1 2017: Pipeline development on track with several key milestones ahead 23
Feb 09, 2017: Molecular Partners reports preliminary unaudited key financials for 2016: Advancements across all therapeutic areas Ongoing strong cash position 26
Corporate Communications 28
Jun 21, 2018: Molecular Partners Names Pamela A. Trail as Chief Scientific Officer; Michael T. Stumpp Assumes Role of Chief Operating Officer of the Company 28
May 12, 2017: Patrick Amstutz Appointed as Chief Executive Officer 29
May 11, 2017: Shareholders of Molecular Partners approved all Board proposals at the Annual General Meeting - Gwen Fyfe elected new Board member 30
Apr 12, 2017: Christian Zahnd appointed as Honorary Chairman of the Board of Directors as he decided not to stand for re-election as member of the Board of Directors at the Annual General Meeting 2017 31
Product News 32
11/09/2017: Molecular Partners Expands and Advances Robust Pipeline of DARPin Therapies in Oncology and Ophthalmology 32
Other Significant Developments 33
Apr 26, 2018: Further MP0250 clinical data and partner interest underline Molecular Partners continued progress of its proprietary oncology compounds 33
Oct 26, 2017: Molecular Partners: Interim Management Statement Q3 2017 36
Appendix 38
Methodology 38
About GlobalData 38
Contact Us 38
Disclaimer 38

List Of Tables

List of Tables
Molecular Partners AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Molecular Partners AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Molecular Partners AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Molecular Partners AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Molecular Partners AG, Deals By Therapy Area, 2012 to YTD 2018 8
Molecular Partners AG, Medical Devices Deals, 2012 to YTD 2018 9
Molecular Partners AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Molecular Partners and AstraZeneca Enter into Partnership 11
Molecular Partners Reinforces Partnership with Allergan 12
Allergan Exercises Option Agreement with Molecular Partners 13
Molecular Partners Raises USD31.7 Million in Private Placement of Shares 14
Molecular Partners Announces Partial Exercise of Underwriters Option for IPO for USD108 Million 15
Molecular Partners AG, Key Competitors 17
Molecular Partners AG, Key Employees 18

List Of Figures

List of Figures
Molecular Partners AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Molecular Partners AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Molecular Partners AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Molecular Partners AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Molecular Partners AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Molecular Partners AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Molecular Partners AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Molecular Partners AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Molecular Partners AG, Medical Devices Deals, 2012 to YTD 2018 9

Molecular Templates Inc (MTEM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Molecular Templates Inc (MTI), formerly Threshold Pharmaceuticals Inc, is a clinical-stage oncology company that discovers and develops biologic therapeutics for cancer. The companys pipeline products include MT-3724, MT-4019, MT-5111, MT-5050

USD 250 View Report

Molecular Health GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Molecular Health GmbH (Molecular Health) is a biomedical company that designs, develops, manufactures and commercializes software systems which performs integrated analysis of clinical and genomic patient data to support treatment

USD 250 View Report

Molecular Partners AG Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Molecular Partners AG Company Profile is a detailed strategic and analytical report on Molecular Partners AG. The 2018 version of the report offers detailed insights into the companys strategies, developments,

USD 200 View Report

Molecular Partners AG (MOLN) - Financial and Strategic SWOT Analysis Review

Molecular Partners AG (Molecular Partners) is a biopharmaceutical company that offers biological drugs. The companys advanced pipeline products comprise abicipar, a designed ankyrin repeat protein based anti-angiogenic drug developed for

USD 300 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available